VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,197,411 | +235.1% | 651,185 | +228.2% | 0.10% | +234.5% |
Q2 2023 | $9,907,896 | -47.2% | 198,396 | -60.4% | 0.03% | -50.0% |
Q1 2023 | $18,781,228 | +29.4% | 501,100 | +65.6% | 0.06% | +18.4% |
Q4 2022 | $14,509,670 | +43.0% | 302,600 | -28.4% | 0.05% | +19.5% |
Q3 2022 | $10,147,000 | – | 422,800 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |